Back HIV Policy & Advocacy Drug Pricing & Patents

Drug Pricing & Patents

BHIVA 2015: HIV Treatment Outcomes No Better with Single-tablet Regimens than Individual Pills

One-pill-a-day HIV treatments such as Atripla, Stribild, Complera, and Triumeq and Triumeq have the same rates of virological failure, drug resistance, and side effects as multiple tablet regimens, according to a meta-analysis presented to the British HIV Association (BHIVA) conference this week in Brighton. Single tablets cost the UK National Health Service (NHS) 5 five times more but have unproven clinical benefits, said Andrew Hill of Chelsea and Westminster Hospital.

alt

Read more:

UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall

The number of people in Africa receiving antiretroviral medications increased from less than 1 million in 2005 to an estimated 7.1 million in 2012, according to a new report from UNAIDS. The report also notes that AIDS-related deaths and new HIV infections have both fallen by about 30% over the past decade.  alt

 

Read more:

DHHS Implements Common Application for HIV Patient Assistance Programs

A common application that allows people with HIV to apply for financial assistance for drugs from multiple companies went into effect on September 12, 2012. Individuals should now be able to obtain a complete antiretroviral regimen with a single form.alt

Read more:

HIV Medical Providers Call for Fair Drug Pricing to Expand Access to Treatment

Practitioners from the American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA) delivered a joint statement to pharmaceutical company executives this week, asking the industry to reconsider its pricing for antiretroviral drugs so that more people in the U.S. and worldwide are able to access treatment. alt

Read more:

AIDS 2012: HIV Drugs Cheaper than Thought, Clinton Report Says

Antiretroviral therapy and related care for people with HIV worldwide would likely cost about 4 times less than previously estimated, meaning that wider global scale-up of treatment is possible, according to a new report by the Clinton Health Access Initiative released ahead of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. alt

Read more: